Ginkgo Bioworks (NYSE:DNA – Get Free Report) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it compare to its peers? We will compare Ginkgo Bioworks to related companies based on the strength of its dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.
Earnings and Valuation
This table compares Ginkgo Bioworks and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Ginkgo Bioworks | $170.15 million | -$312.76 million | -2.02 |
| Ginkgo Bioworks Competitors | $2.26 billion | $55.88 billion | -7.48 |
Ginkgo Bioworks’ peers have higher revenue and earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 54.3% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by company insiders. Comparatively, 15.2% of shares of all “Life Sciences Tools & Services” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Ginkgo Bioworks and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ginkgo Bioworks | -249.20% | -56.97% | -24.60% |
| Ginkgo Bioworks Competitors | -487.63% | 40.45% | -13.30% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Ginkgo Bioworks and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ginkgo Bioworks | 2 | 2 | 0 | 0 | 1.50 |
| Ginkgo Bioworks Competitors | 957 | 3197 | 5533 | 179 | 2.50 |
Ginkgo Bioworks currently has a consensus target price of $7.00, suggesting a potential downside of 17.60%. As a group, “Life Sciences Tools & Services” companies have a potential upside of 1.38%. Given Ginkgo Bioworks’ peers stronger consensus rating and higher probable upside, analysts plainly believe Ginkgo Bioworks has less favorable growth aspects than its peers.
Volatility and Risk
Ginkgo Bioworks has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks’ peers have a beta of 0.94, indicating that their average stock price is 6% less volatile than the S&P 500.
Summary
Ginkgo Bioworks peers beat Ginkgo Bioworks on 9 of the 12 factors compared.
Ginkgo Bioworks Company Profile
Ginkgo Bioworks is a biotechnology company that develops and engineers microorganisms and other cells for use in commercial products. Its platform combines biological research, automation, and software to help customers design, build, and test organisms with desired characteristics. The company provides cell-engineering services and capabilities to organizations in areas including pharmaceuticals, agriculture, food, and industrial chemicals. Its work can include developing and optimizing microbial strains and supporting the production of ingredients and other materials.
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
